Prompts winter weather advisories as cold air moves in Friday night

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

The COVID-19 vaccines were developed at a dizzying speed. Chinese researchers shared the genetic sequence of the virus on Jan. 11, 2020. Just

 Moderna had a vaccine ready to test. Pfizer wasn’t far behind. 

Both companies built their vaccines using mRNA technology — a relatively new branch of genetic research that harnesses the body’s own ability to repair itself. Human cells rely on proteins to function. Messenger ribonucleic acid, or mRNA, tells our cells which proteins to make. 

If scientists can edit that mRNA to direct our cellular mechanisms to make new and different proteins — as they did with the COVID-19 vaccines — the potential is almost limitless. 

Buoyed by the speed and success of the COVID-19 vaccines, researchers are 

 on vaccines for influenza, HIV, malaria, tuberculosis and hepatitis C. 

And then there’s cancer. Until now, a vaccine for most cancers seemed out of reach, since cancer is so complex. But doctors are now imagining a future where mRNA technology is used to create specific therapies that could train the body to attack distinct tumors. 

? Monday, host Kerri Miller talked with two scientists working on the front lines of this emerging technology. 

To listen to the full conversation you can use the audio player above.

Subscribe to the MPR News with Kerri Miller podcast on: 

Science

Health

Shows

Big Books & Bold Ideas with Kerri Miller

COVID-19

Host

Author

Both the Moderna and Pfizer COVID-19 vaccines were built using new mRNA research, to astounding success. What’s the next big thing mRNA science could tackle?

COVID-19 vaccines are just the beginning for mRNA innovations

Go Deeper.

Like this?